KR101713557B1 - Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease - Google Patents
Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease Download PDFInfo
- Publication number
- KR101713557B1 KR101713557B1 KR1020150051766A KR20150051766A KR101713557B1 KR 101713557 B1 KR101713557 B1 KR 101713557B1 KR 1020150051766 A KR1020150051766 A KR 1020150051766A KR 20150051766 A KR20150051766 A KR 20150051766A KR 101713557 B1 KR101713557 B1 KR 101713557B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- black
- mixture
- composition
- shark
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present invention relates to a pharmaceutical composition for the prevention or treatment of hypertension, which comprises as an active ingredient an extract of black shafts or a mixture of black shafts and pristine color mixtures or a mixture of black shafts and prunus extract. According to various embodiments of the present invention, the black shark extract or the mixture of the black shark and the pale color mixture or the mixture of the black shark extract and the pale color extract of the present invention inhibits ACE (angiotensin converting enzyme), thereby effectively increasing the blood pressure caused by the action of angiotensin converting enzyme It is useful as a medicament for preventing or treating cardiovascular diseases, that is, hypertension or hypertensive heart disease, or a health functional food.
Description
The present invention relates to a pharmaceutical composition for the prevention or treatment of cardiovascular diseases, which comprises a black shark extract or a mixture of a black shark extract and a colorless extract as an active ingredient.
Cardiovascular disease is the second most common cause of death after cancer among Korean adults. Hypertension is a major risk factor for cardiovascular disease and is a disease that causes fatal diseases such as stroke, myocardial infarction, congestive heart failure, kidney disease, and peripheral vascular disease .
Hypertension is the most important and well-known factor among the correctable risk factors for ischemic stroke, which accounts for about 80% of strokes. Systolic blood pressure increases from 20 mmHg above 115 mmHg and diastolic blood pressure increases from 10 mmHg above 75 mmHg The incidence of stroke increases by two times with each increase. Hypertension is also closely related to the incidence of myocardial infarction, heart failure, and stroke. It is known that the incidence of cardiovascular disease is doubled every 20 mmHg of systolic blood pressure and 10 mmHg of diastolic blood pressure.
Hypertension treatment can be divided into lifestyle improvement and drug therapy. Lifestyle practices that correct lifestyle include salt restriction, obesity weight loss, alcohol restriction, exercise therapy, smoking cessation, increased fruit and vegetable intake, and restriction of cholesterol and saturated fatty acid intake. Lifestyle therapy not only strengthens blood pressure, but also enhances the action of coercive agents and prevents the complications of cardiovascular disease or risk factors. Improvement of lifestyle is a basic treatment but often does not reach the target blood pressure, and it is necessary to be concurrent with most pharmacotherapy.
Many antihypertensive agents have been developed and used for the treatment of hypertension. Depending on the mechanism of action and the point of action, diuretics, sympathomimetics (α, 2-adrenergic antagonist, β-adrenergic antagonist), vasodilator, calcium channel antagonist channel blockers and angiotensin converting enzyme (ACE) inhibitors (Mann, SJ., Neurogenic essential hypertension revisited: The case for incresed clinical and research attention, American Journal of Hypertension, 16, Escobales, N., Crespo, MJ., Oxidative-nitrosative stress in hypertension, Current Vascular Pharmacology, 3, pp. 231-246, 2005).
However, there is still a need for new drugs that can treat hypertension, with few side effects.
On the other hand, the pale color is the tubercle of poppies and other inbred plants. Berberine, 1-Canadine, Protopine, 1-Tetrahydrocoptisine, It is a medicinal substance that facilitates the circulation of the blood and the circulation. It facilitates the circulation of the tile and blood against the pain accompanying the blood or gagged symptoms, so that the analgesics, sedatives, antispasmodics And has a pharmacological effect such as inhibition of gastric ulcer.
Therefore, color is used in the oriental medicine, analgesic medicine, antiepileptic medicine as antiepileptic medicine, anti-ulcer, etc. It is prescribe to the pain which the body nurses and the pain felt by the nerve stimulation, that is, abdominal pain, back pain, stomach pain and headache. The blood circulation in the body does not work well due to menstrual irregularities and dysmenorrhoea is prescribed in the color of the body (Kim Dae Keun et al., Hoko Shigakusha, Shinil Sangsaja, pp.274-275, 2005).
Pharbitidis Semen refers to the seeds of Pharbitis nil choisy (convolvulaceae), which is a subspecies in the oriental medicine and the private sector. Secretion, abdominal pain, swelling, abdominal distension, and constipation. The black shafts contain about 11% of fatty oil and 2% of pharbitin, a resinous glycoside, and are known to have subcutaneous, diuretic and insecticidal action (Korean Pharmacopoeia V, Part 2, 651). It is also effective in improving seawater, asthma and constipation, and is used as a cosmetic composition for massage which removes impurities from the skin. Also, it is effective when you do not see diuretic - urine. It is especially used for high fever disease. It can be used when revenge is cold and the body has swelling. Gadam work - effects on sputum, cough, asthma and so on. Insecticidal action - It is used as an old restriction of roundworms, tapeworms, etc. It is used for the purpose of relieving various symptoms accompanied by abdominal pain caused by parasites.
However, none of the above-mentioned documents have been disclosed or disclosed in relation to hypertension-related diseases of color and blackness.
A problem to be solved by the present invention is to provide a pharmaceutical composition for prevention or treatment of cardiovascular diseases comprising (i) an extract of black shark or (ii) an extract of a black shade and a purple color mixture or (iii) a mixture of a black shark extract and a pale- .
Another object to be solved by the present invention is to provide a method for preventing or improving cardiovascular diseases, which comprises (i) an extract of black shark or (ii) an extract of black shade and color mixture, or (iii) To provide a food composition.
According to one representative aspect of the present invention there is provided a pharmaceutical composition for the prevention or treatment of cardiovascular diseases comprising (i) an extract of a black shark or (ii) an extract of a black-and-white mixture, or (iii) a mixture of a black- Lt; / RTI >
According to another representative aspect of the present invention, there is provided a method for preventing or improving a cardiovascular disease comprising (i) an extract of a black shark or (ii) an extract of a black-and-white mixture, or (iii) a mixture of a black- Lt; / RTI >
According to various embodiments of the present invention, a mixture of (i) a black shark extract of the present invention or (ii) an extract of a black-and-white mixture with a black shaft or (iii) a mixture of a black shark extract and a prickly extract may inhibit angiotensin converting enzyme It can effectively be used as a medicament for the prevention and treatment of cardiovascular diseases, i.e., hypertension or hypertensive heart disease, or a health functional food, because it not only effectively suppresses an increase in blood pressure caused by the action of enzymes but also has high safety to human body have.
Hereinafter, terms used in the present invention will be described.
As used herein, the term "prophylactic " means any action that inhibits cardiovascular disease by administration of the composition of the present invention.
As used herein, the terms " treatment "and" improvement "refer to any action by which administration of the composition of the present invention improves or alleviates cardiovascular disease.
The term "administering" as used herein is meant to provide any desired composition of the invention to an individual by any suitable method.
The term "individual" as used herein refers to all animals, including human, monkey, dog, goat, pig or rat, suffering from cardiovascular disease or obesity by administering the composition of the present invention.
As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat cardiovascular disease at a reasonable benefit or risk rate applicable to medical treatment, including the severity of the subject's obesity, the activity of the drug, The drug's sensitivity, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including simultaneously used drugs, and other factors well known in the medical arts.
Hereinafter, various aspects and various embodiments of the present invention will be described in more detail.
According to one aspect of the present invention there is provided a pharmaceutical composition for the prevention or treatment of cardiovascular diseases comprising (i) an extract of black shark or (ii) an extract of a black-and-white mixture, or (iii) a mixture of a black- / RTI >
In one embodiment of the present invention, the weight ratio (w / w) between the black side and the color tone is not particularly limited, but is preferably 1: 0.05 To 1:20, and the weight ratio (w / w) of the black side to the precursor color is 1: 0.1 to 1:10, which is more preferable because it has an effective effect that the ACE inhibitory activity exceeds 55%. When the ratio is less than 1: 0.1 or more than 1:10, the inhibitory effect on ACE (angiotensin converting enzyme) associated with cardiovascular diseases, ie, the blood pressure increase, causes the ACE inhibitory activity to decrease to 52% or less .
In addition, the weight ratio (w / w) of the black extract to the color extract is not particularly limited as long as the active ingredient is a mixture of (iii) a black shark extract and a pale color extract, and (ii) , Preferably 1: 0.05 to 1: 20, and the weight ratio (w / w) of the black extract to the colorless extract is 1: 0.1 to 1:10, the ACE inhibitory activity is effectively 55% More preferable. When the ratio is less than 1: 0.1 or more than 1:10, the inhibitory effect on ACE (angiotensin converting enzyme) associated with cardiovascular diseases, ie, the blood pressure increase, causes the ACE inhibitory activity to decrease to 52% or less .
(Ii) the extract of the black shade and the purple color mixture is obtained from the mixture of the black shade and the purple color, and the mixture of the black color and the purple color is mixed with water, a lower alcohol having 1 to 4 carbon atoms, And is extracted with a mixed solvent.
(Iii) a mixture of the black shark extract and the pale color extract is a mixture of the black shark extract obtained from the above-mentioned black shrinkage and the pale-color extract obtained from said pale shade, said black shark extract and said pale- A lower alcohol, or a mixed solvent thereof.
The mixture of the black and white extracts may be a mixture of the extracts obtained by mixing the black shales and the pale colors at the above weight ratios, or the extracts or the respective extracts at the above weight ratios.
More specifically, the extract of the present invention can be obtained as follows. First, the mixture of the black shade or the pale color of the present invention or the mixture of the black color and the pale color is washed and dried, respectively, and then pulverized with a dry herb or a pulverizer to obtain a pulverized herb. The pulverized herb is pulverized with a grinder to be pulverized, Preferably 1 to 25 times, and preferably 5 to 15 times, water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, preferably ethanol, at 20 to 100 占 폚, preferably 45 to 75 占 폚 Extraction is carried out once to five times with an extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction for about 1 to 100 hours, preferably 65 to 80 hours at the extraction temperature, followed by filtration under reduced pressure and lyophilization .
The pharmaceutical composition according to the present invention is a pharmaceutical composition for preventing or treating cardiovascular diseases, preferably hypertension or hypertensive heart disease.
Generally, hypertension refers to a state in which the systolic blood pressure, diastolic blood pressure, or mean arterial pressure is kept higher than the normal level in a stable state. In humans, adult normal systolic and diastolic blood pressures are 120 mmHg and 80 mmHg, mean arterial pressure is 100 mmHg, and pulse pressure is 40 mmHg. However, it is often considered normal if the systolic blood pressure is within 140 mmHg and the diastolic blood pressure is within 90 mmHg, because there is a slight difference between individuals. Therefore, hypertension refers to when the systolic blood pressure is more than 140 mmHg and the diastolic blood pressure is more than 90 mmHg.
Hypertensive heart disease is a disease caused by an abnormally elevated blood pressure. Examples include, but are not limited to, coronary artery disease, cerebrovascular disease, peripheral vascular disease, aortic disease, renal dysfunction, heart failure, and visual disturbance. Examples of the coronary artery disease include angina pectoris and myocardial infarction. Examples of cerebrovascular diseases include stroke, cerebral hemorrhage, and cerebral infarction. In addition, the pharmaceutical composition according to the present invention can also be applied to the treatment or prevention of complications such as diabetes, hyperlipidemia, arteriosclerosis and asthma, chronic lung disease and the like.
The pharmaceutical compositions of the present invention may be administered individually or in combination with other types of hypotensive agents. The pharmaceutical compositions of the present invention may be administered alone, but may be administered with a pharmaceutical carrier selected on the basis of the generally chosen route of administration and standard pharmaceutical particles.
The pharmaceutical composition of the present invention can be administered to mammals by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, subcutaneous, intravenous, intramuscular or intraperitoneal administration.
For oral administration, the pharmaceutical compositions of the present invention may be formulated in solid form such as capsules, tablets and powders or in liquid form such as elixir syrups and suspensions. For parenteral administration, it may be formulated in an aseptic liquid form.
Capsules may contain active ingredients such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like, and powdered carriers. In addition, compressed tablets can be prepared using a diluent. Both tablets and capsules can be manufactured as sustained release products to allow continuous release of the drug over a period of several hours. Compressed tablets may be coated with sugar or film.
Pharmaceutical compositions in liquid form for oral administration may contain pigments and flavors to enhance patient preference.
Pharmaceutical formulations in liquid form for parenteral administration may contain water as a suitable carrier, suitable oils, saline, aqueous dextrose (glucose) and glycols such as propylene glycol or polyethylene glycol. Preferably, it may comprise a water soluble active ingredient salt, a suitable stabilizing agent, and a buffering material. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid. In addition, the pharmaceutical composition in liquid form for parenteral administration may contain a preservative such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
The dosage of the pharmaceutical composition for cardiovascular diseases according to the present invention can be adjusted according to age, health, weight, disease severity, and the number of treatments. Generally, the daily dose of the hypotensive composition of the present invention is preferably 1 to 500 mg per 1 kg of body weight. 1 to 500 mg / kg / day, preferably 50 to 300 mg / kg / day when applied at least once.
In addition, a mixture of (i) a black shark extract or (ii) an extract of a black-and-white mixture of the present invention, or (iii) a mixture of a black shark extract and a pale extract of the present invention lower blood pressure to prevent a cardiovascular disease, i.e., hypertension or hypertensive heart disease May be added to the food for the purpose of.
It is preferable that the mixture of (i) the black shark extract or (ii) the black shrink and the mixture of the color mixture contained in the food composition of the present invention or (iii) the mixture of the black shark extract and the pale color extract is purified through column chromatography, May also be included. Foods to which (i) an extract of black shark or (ii) an extract of a black-and-white mixture, or (iii) a mixture of a black shark extract and a prickly extract may be mentioned, including but not limited to various foods, meats, Snacks, snacks, noodles, gums, ice cream, alcoholic beverages, tea bags, instant tea, granules, spices, tablets and capsules.
A mixture of the (i) black shark extract of the present invention or (ii) an extract of a black-and-white mixture with black shrink or (iii) a black shark extract and a pale extract may be added to the food as they are or may be used together with other food or food ingredients, Can be appropriately used. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term ingestion intended for health and hygiene purposes or health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount in the above range.
The health functional beverage composition of the present invention is not particularly limited to the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 of the composition of the present invention.
In addition to the above, a mixture of (i) a black shark extract or (ii) an extract of a black-and-white mixture with a black shark or (iii) a black-shark extract and a pale yellowish extract according to the present invention may contain various nutrients, vitamins, minerals (electrolytes) Used in flavors such as flavorings, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, And the like. In addition, the mixed extract of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The ratio of such additives is not so important, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the mixed extract of the present invention.
Hereinafter, the present invention will be described in more detail with reference to Examples and the like, but the scope and content of the present invention can not be construed to be limited or limited by the following Examples. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the present invention as set forth in the following claims. It is natural that it belongs to the claims.
EXAMPLES 1 to 21: Preparation of extracts of black shrubs and color mixtures.
Corydalis Tuber and Pharbitis seed, which were dried on the herb medicinal materials of Kyungdong market, were purchased and used to remove the contaminants. The dry color and black shafts were crushed. The pulverized black shafts and pre-existing colors were mixed by the weights shown in Table 1, followed by 8 times (v / w) 50% aqueous ethanol solution, followed by cold-pressing at room temperature for 48 hours. The filtrate was concentrated under reduced pressure at 45-65 占 폚 and then lyophilized to obtain an extractive soft X-ray of a black-and-white mixture.
Example 22: Preparation of black shrimp extract
A black shroud extract was obtained using substantially the same method as in Example 1, except that 20 g of the crushed black shafts were used.
COMPARATIVE EXAMPLE 1: Preparation of color-proof extract
A precursor extract was obtained using substantially the same method as in Example 1, except that 20 g of the crushed pale color was used.
Experimental Example 1: Confirmation of ACE (angiotensin converting enzyme) inhibition
The ACE inhibitory effect of the extracts of black shark, purple color extract and black shale and pale yellow color was evaluated by ACE measurement kit (Kushman DW et al., Biochem. Pharm., 20, pp 1637-1647, 1971) (Dojindo) in vitro cell free system. Buffer 1 was prepared by adding deionized water instead of the sample, and blank 2 was added by adding deionized water instead of the sample and enzyme. As a positive control, 10 mg (Enalapril Tablets 10 mg LGCI, LG Life Science), a commercially available ACE inhibitor, was used.
The enzyme activity inhibition rate was calculated by the following equation (1).
[Equation 1]
ACE inhibitory activity = [(A blank1 -A sample ) / (A blank1 -A blank2 )] X 100
As a result, as shown in Table 2, ACE inhibitory activity by the single treatment of black shrimp extract increased ACE inhibitory activity in a concentration-dependent manner from 0.5 μg / ml to 10.0 μg / ml, and was about 58% at 10.0 μg / ACE < / RTI >
The ACE inhibitory activity was increased in a concentration-dependent manner from 0.5 μg / ml to 10.0 μg / ml by ACE inhibitor alone, indicating that ACE inhibition activity was about 63% at 10.0 μg / ml treatment. In order to compare ACE inhibitory activities according to the blending ratio of black shade and pale shade, mixed extracts of various mixing ratios were treated. When each herbal medicine was treated with 1.0 μg / ml alone, about 37% of black extract and 46% of colorectal extract were inhibited.
As in Examples 1 to 21, when the mixture of each herbal medicine was mixed at a mixing ratio of 1: 0.05 to 1:20, the inhibitory activity was 50-91% when treated with 1.0 μg / ml of extract, Inhibitory activity was increased. In particular, it was confirmed that the highest effect was obtained in the 1: 5 mixed extract of black shale and pale color, at about 91% (Table 2).
As a result of examining the effect of the mixing ratio of each herbal medicine on the ACE inhibitory activity in the extracts of the black shrub and the pale yellow mixture, it was found that the mixture of the above black shrunken and pale yellow was mixed at a mixing ratio of 20: 1 (1: 0.05) Extracts were prepared and treated with 1.0 μg / ml, the inhibitory activities were superior to those obtained by treatment with 1 μg / ml of herbal medicine extract alone. Thus, compositions for prevention or treatment of cardiovascular diseases and prevention or improvement of cardiovascular diseases Can be used as a health food composition. However, in the case of mixing the herbal medicines in the black shrinkage and pale yellow color mixed extracts at a ratio of 20: 1 and 1:20, it is 50% to 52%, which is about half of the ACE inhibitory activity. To 1:10 are preferable.
In particular, when the mixing ratio (w / w) of each herbal medicine is 1: 5 in the extract of the black shade and the color mixture, the mixture has the ACE inhibitory activity of 90% or more, Do. In addition, the extracts of the black-and-white mixture at the above 1: 5 mixing ratio have an ACE inhibitory activity that is more than 30% higher than that of the black extract and ascorbic acid extract of 10-fold concentration alone and 13% higher than that of nilapril.
That is, the ACE inhibitory activity of 1 μg / ml prepared by mixing the black-and-white mixture according to the present invention at a mixing ratio of 1: 1, the black extract of 0.5 μg / ml (20.09%) using herbal medicine alone, It was confirmed that the inhibitory activity was more than 12% higher than the ACE inhibitory activity calculated by adding 1: 1 of the extract (0.5 μg / ml (24.58%)). Therefore, the present invention has remarkably excellent effects .
Mixed extract
Claims (15)
Wherein the weight ratio (w / w) of the black shade to the precursor color is 1: 0.05 to 1:20.
Wherein the weight ratio (w / w) of the black extract to the colorectal extract is 1: 0.05 to 1:20.
The weight ratio (w / w) of the above-mentioned black shafts and purple or black shampoos and pale yellow extracts was 1: 5 Or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the manufacture of a medicament for preventing or treating hypertension or hypertensive heart disease.
Wherein the weight ratio (w / w) of the black shade to the color tone is 1: 0.05 to 1:20.
Wherein the weight ratio (w / w) of the black extract to the color extract is 1: 0.05 to 1:20.
The weight ratio (w / w) of the above-mentioned black shafts and purple or black shampoos and pale yellow extracts was 1: 5 Or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the prevention or amelioration of hypertension or hypertensive heart disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150051766A KR101713557B1 (en) | 2015-04-13 | 2015-04-13 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
| PCT/KR2016/003137 WO2016167493A2 (en) | 2015-04-13 | 2016-03-28 | Pharmaceutical composition for preventing or treating cardiovascular diseases, containing pharbitis seed extract or mixture of pharbitis seed extract and corydalis extract as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150051766A KR101713557B1 (en) | 2015-04-13 | 2015-04-13 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160121912A KR20160121912A (en) | 2016-10-21 |
| KR101713557B1 true KR101713557B1 (en) | 2017-03-22 |
Family
ID=57126634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150051766A KR101713557B1 (en) | 2015-04-13 | 2015-04-13 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101713557B1 (en) |
| WO (1) | WO2016167493A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005320323A (en) | 2004-04-09 | 2005-11-17 | Taisho Pharmaceut Co Ltd | Lipase inhibitor |
| JP2011519368A (en) | 2008-05-01 | 2011-07-07 | アフェクサ ライフ サイエンシーズ インコーポレイテッド | Pharmaceutical composition comprising an extract of yellow ream and bitter tea useful for reducing blood lipid concentration |
| US20130045987A1 (en) | 2010-05-03 | 2013-02-21 | Dignity Health | Novel methods of use of tetrahydroberberine (thb) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100554270C (en) * | 2004-12-29 | 2009-10-28 | 中国人民解放军第二军医大学 | Deydrokaividing, dehydrogenation apocavidine and preparation of compositions method thereof |
| EP2029150A4 (en) * | 2006-02-28 | 2009-12-16 | Dong A Pharm Co Ltd | Extract of herbal and the composition containing the same |
| WO2014000119A1 (en) * | 2012-06-25 | 2014-01-03 | 佛山市顺德区合生源医药研发有限公司 | Anti-tachyarrhythmia formulation and preparation method thereof |
-
2015
- 2015-04-13 KR KR1020150051766A patent/KR101713557B1/en active IP Right Grant
-
2016
- 2016-03-28 WO PCT/KR2016/003137 patent/WO2016167493A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005320323A (en) | 2004-04-09 | 2005-11-17 | Taisho Pharmaceut Co Ltd | Lipase inhibitor |
| JP2011519368A (en) | 2008-05-01 | 2011-07-07 | アフェクサ ライフ サイエンシーズ インコーポレイテッド | Pharmaceutical composition comprising an extract of yellow ream and bitter tea useful for reducing blood lipid concentration |
| US20130045987A1 (en) | 2010-05-03 | 2013-02-21 | Dignity Health | Novel methods of use of tetrahydroberberine (thb) |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016167493A3 (en) | 2016-12-08 |
| KR20160121912A (en) | 2016-10-21 |
| WO2016167493A2 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
| JP2011509996A (en) | Composition for prevention and treatment of cardiovascular disease containing dankobai extract | |
| KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
| KR102538751B1 (en) | Pharmaceutical composition and food composition for treating erectile dysfunction | |
| KR100805865B1 (en) | Anti-thrombus agent comprising extract of herbal mixture | |
| KR101713557B1 (en) | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease | |
| JP5358627B2 (en) | A pharmaceutical composition for preventing or treating ischemic disease or degenerative brain disease, or for improving memory impairment, comprising Tarayo extract as an active ingredient | |
| WO2014133286A1 (en) | Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases | |
| KR20210058760A (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR102533252B1 (en) | Composition for preventing, improving or treating diseases related to vascular endothelial cell activity regulation, comprising Java pepper extract as an active ingredient | |
| KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
| KR102441302B1 (en) | Composition for anti-cancer containing deacetyl torilin as effective component | |
| KR20190097332A (en) | Composition for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Cornus officinalis as effective component | |
| KR20130082250A (en) | Composition for preventing or improving the hypertension containing parthenocissus tricuspidata extract | |
| KR20120073797A (en) | Pharmaceutical composition comprising for preventing and treating an articular rheumatism, extract from the mixture of ponciri fructus, lonicerae flos and angelicae dahuricae radix | |
| KR20180047659A (en) | Composition for preventing and improving atherosclerosis comprising extract of Agarum clathratum | |
| KR102126574B1 (en) | Antithrombotic agent containing an extract of Angelica gigas Nakai | |
| WO2013133677A1 (en) | Composition containing reaction mixture of red-ginseng extract and persimmon vinegar for preventing or treating vascular diseases | |
| JP2002212085A (en) | Uric acid value-reducing agent | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| KR20180037496A (en) | Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising Dryopteris crassirhizpma extract as effective component | |
| KR20220037530A (en) | A composition for improving, preventing and treating of vascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 4 |